Roivant Sciences (ROIV) Stock Price
Roivant Sciences Price
Roivant Sciences (ROIV) Stock | ISIN BMG762791017 | WKN A3C4MS. The current Roivant Sciences stock price is 28.58 USD (2026). Revenue is 9.85 M USD. Net income is -930.8 M USD. The P/E ratio is -22.27. Market capitalization is 20.73 B USD. Roivant Sciences operates in the Health sector.
Roivant Sciences stock price
Details
Stock Price
ⓘHow to Read This Chart
This chart tracks the historical stock price of Roivant Sciences over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.
Total Return vs. Price Return
The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.
Intraday Price Data
When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Roivant Sciences stock reacts to market openings, earnings releases, or breaking news throughout the trading session.
What to Look For
Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Roivant Sciences's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.
| Date | Roivant Sciences Price |
|---|
Roivant Sciences Revenue, EBIT, Net Income
3 Years
5 Years
10 Years
25 Years
Max
Details
Roivant Sciences Income Statement, Balance Sheet, Cash Flow Statement
| REVENUE (M USD) |
|---|
| REVENUE GROWTH (%) |
| GROSS MARGIN (%) |
| GROSS INCOME (M USD) |
| NET INCOME (M USD) |
| NET INCOME GROWTH (%) |
| SHARES (M) |
| DOCUMENTS |
Details
Income Statement Key Figures
ⓘRevenue and Revenue Growth
Revenue is the starting point of every income statement — it measures the total sales Roivant Sciences generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.
Gross Margin
Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Roivant Sciences retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Roivant Sciences's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.
EBIT and EBIT Margin
EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.
Net Income and Earnings Per Share (EPS)
Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.
Shares Outstanding
The total number of shares Roivant Sciences has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.
Analyst Estimates
The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Roivant Sciences's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.
Roivant Sciences stock margins
3 Years
5 Years
10 Years
25 Years
Max
Details
Roivant Sciences Stock Revenue, EBIT, Earnings per Share
3 Years
5 Years
10 Years
25 Years
Max
Details
Roivant Sciences business model & stock analysis
Roivant Sciences SWOT Analysis
Strengths
1. Strong Research and Development capabilities, enabling development of innovative drugs and therapies.
2. Well-established partnerships with leading pharmaceutical companies, providing access to resources, expertise, and potential collaborations.
3. Diverse portfolio of drug candidates across various therapeutic areas, reducing dependency on a single product.
Weaknesses
1. Relatively small market presence compared to larger pharmaceutical companies, limiting brand recognition and market share.
2. High dependence on external sources for funding research and development activities, making the company vulnerable to changes in funding availability.
3. Limited manufacturing capabilities, potentially impacting the speed and efficiency of drug production.
Opportunities
1. Growing demand for innovative and personalized healthcare solutions, creating opportunities for Roivant Sciences Ltd to capitalize on its R&D expertise.
2. Expansion into emerging markets with favorable regulatory environments, allowing for increased market penetration.
3. Potential collaborations with academic institutions and research organizations to further enhance R&D capabilities.
Threats
1. Intense competition within the pharmaceutical industry, with larger players having significant resources and established market positions.
2. Stringent regulatory requirements and lengthy approval processes, posing challenges and delays in bringing new drugs to market.
3. Uncertainty surrounding healthcare policies and reimbursement systems, potentially impacting the demand and pricing of drugs.
Roivant Sciences Segments
Roivant Sciences Revenue by Segment
3 Years
Max
Details
Roivant Sciences Eulerpool Fair Value
Roivant Sciences historical P/E ratio, EBIT multiple, and P/S ratio
Roivant Sciences annual returns
Details
Annual Return
ⓘWhat This Chart Shows
This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.
Price Return
Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.
Dividend Return
Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.
What to Look For
Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.
Roivant Sciences shares outstanding
3 Years
5 Years
10 Years
25 Years
Max
Details
Roivant Sciences Earnings Estimates
Roivant Sciences Earnings Estimates
| Date | EPS estimate | Revenue Estimate | Quarterly report |
|---|---|---|---|
| 11/11/2024 | -0.26USD | 50.2 MUSD | 2025 Q2 |
| 6/26/2024 | -0.33USD | 35.41 MUSD | 2024 Q4 |
| 2/12/2024 | -0.33USD | 31.77 MUSD | 2024 Q3 |
| 11/14/2022 | -0.44USD | 5.74 MUSD | 2023 Q2 |
EESG©
Eulerpool ESG Scorecard© for the Roivant Sciences stock
EEnvironment
20
Environment
SSocial
20
Social
GGovernance (Corporate Governance)
4
Governance (Corporate Governance)
The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.
Roivant Sciences shareholder structure
| % | Name |
|---|---|
14.17839% | |
8.26482% | |
7.65035% | |
6.74418% | |
5.41023% | |
4.89808% | |
4.71988% | |
4.60059% | |
4.05043% | |
2.80817% |
Roivant Sciences Executives and Management Board
Dr. Mayukh Sukhatme
(49)President, Chief Investment Officer, Director · since 2021
Mr. Matthew Gline
(41)Chief Executive Officer, Director · since 2017
Dr. Eric Venker
(38)President and Immunovant Chief Executive Officer
Mr. Richard Pulik
(46)Chief Financial Officer
Ms. Jennifer Humes
(44)Chief Accounting Officer
Frequently asked questions about Roivant Sciences
Roivant Sciences Ltd has a unique business model focused on creating and developing innovative biopharmaceutical companies. They identify and acquire promising drug candidates from research organizations and pharmaceutical companies, and then allocate resources to further develop and commercialize these potential therapies. By operating a centralized infrastructure, Roivant provides expertise in areas such as clinical development, regulatory affairs, and commercialization, enabling their subsidiary companies to focus on scientific advancements. Their mission is to transform the traditional drug development process and bring important therapies to patients in need. Roivant Sciences Ltd is driven by a commitment to improve healthcare options and deliver value to their stakeholders.
Roivant Sciences stock
Roivant Sciences Peer Group
Roivant Sciences Ticker
Roivant Sciences FIGI
All fundamentals and in-depth analysis of Roivant Sciences
Our stock analysis for Roivant Sciences Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Roivant Sciences Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.